



Clinical trial results:

Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma who Have Had Disease Progression on Sorafenib or Are Not Eligible to Receive Sorafenib

Estudio en fase 2 aleatorizado de LY2157299 en pacientes con carcinoma hepatocelular que han presentado progresión de la enfermedad con sorafenib o no son aptos para recibir sorafenib

Summary

EudraCT number	2010-022338-10
Trial protocol	DE ES IT
Global end of trial date	

Results information

Result version number	v1
This version publication date	20 June 2020
First version publication date	20 June 2020

Trial information

Trial identification

Sponsor protocol code	H9H-MC-JBAK
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01246986
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 13665

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	06 June 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	06 June 2019
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 March 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	New Zealand: 23
Country: Number of subjects enrolled	United States: 41
Country: Number of subjects enrolled	Italy: 40
Country: Number of subjects enrolled	Australia: 5
Country: Number of subjects enrolled	France: 69
Country: Number of subjects enrolled	Germany: 21
Country: Number of subjects enrolled	Spain: 5
Worldwide total number of subjects	204
EEA total number of subjects	135

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	99
From 65 to 84 years	101
85 years and over	4

Subject disposition

Recruitment

Recruitment details:

No Text Available

Pre-assignment

Screening details:

Participants who had progressive disease or death are defined as completed.

Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part A Cohort 1 - 160 mg LY2157299

Arm description:

80 mg LY2157299 given orally given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).

Arm type	Experimental
Investigational medicinal product name	LY2157299
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).

Arm title	Part A Cohort 2 - 300 mg LY2157299
------------------	------------------------------------

Arm description:

150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).

Arm type	Experimental
Investigational medicinal product name	LY2157299
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).

Arm title	Part B - 300 mg LY2157299
------------------	---------------------------

Arm description:

150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).

Arm type	Experimental
Investigational medicinal product name	LY2157299
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).

Arm title	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
------------------	--

Arm description:

80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).

Arm type	Experimental
Investigational medicinal product name	Sorafenib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

400 mg Sorafenib BID on days 1 to 28 (28-day cycle).

Investigational medicinal product name	LY2157299
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).

Arm title	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib
------------------	--

Arm description:

150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).

Arm type	Experimental
Investigational medicinal product name	LY2157299
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).

Investigational medicinal product name	Sorafenib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

400 mg Sorafenib BID on days 1 to 28 (28-day cycle).

Arm title	Part D Cohort 1 - 160 mg LY2157299 + ramucirumab
------------------	--

Arm description:

80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	LY2157299
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).

Investigational medicinal product name	Ramucirumab
Investigational medicinal product code	LY30098016
Other name	Cyramza
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

8 mg/kilogram (kg) Ramucirumab intravenous (IV) on days 1 and 15 (28-day cycle).

Arm title	Part D Cohort 2 - 300 mg LY2157299 + ramucirumab
------------------	--

Arm description:

150 mg LY2157299 given twice orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle).

Arm type	Experimental
Investigational medicinal product name	LY2157299
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).

Investigational medicinal product name	Ramucirumab
Investigational medicinal product code	LY30098016
Other name	Cyramza
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

8 mg/kg Ramucirumab IV on days 1 and 15 (28-day cycle).

Number of subjects in period 1	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299
Started	37	72	40
Received at Least 1 Dose of Study Drug	37	72	40
Completed	34	67	34
Not completed	3	5	6
Consent withdrawn by subject	3	4	3
On Treatment	-	-	-
Lost to follow-up	-	1	3

Number of subjects in period 1	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib	Part D Cohort 1 - 160 mg LY2157299 + ramucirumab
Started	3	44	3

Received at Least 1 Dose of Study Drug	3	44	3
Completed	3	39	2
Not completed	0	5	1
Consent withdrawn by subject	-	4	-
On Treatment	-	1	-
Lost to follow-up	-	-	1

Number of subjects in period 1	Part D Cohort 2 - 300 mg LY2157299 + ramucirumab
Started	5
Received at Least 1 Dose of Study Drug	5
Completed	5
Not completed	0
Consent withdrawn by subject	-
On Treatment	-
Lost to follow-up	-

Baseline characteristics

Reporting groups

Reporting group title	Part A Cohort 1 - 160 mg LY2157299
Reporting group description: 80 mg LY2157299 given orally given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).	
Reporting group title	Part A Cohort 2 - 300 mg LY2157299
Reporting group description: 150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).	
Reporting group title	Part B - 300 mg LY2157299
Reporting group description: 150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).	
Reporting group title	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Reporting group description: 80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).	
Reporting group title	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib
Reporting group description: 150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).	
Reporting group title	Part D Cohort 1 - 160 mg LY2157299 + ramucirumab
Reporting group description: 80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).	
Reporting group title	Part D Cohort 2 - 300 mg LY2157299 + ramucirumab
Reporting group description: 150 mg LY2157299 given twice orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle).	

Reporting group values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299
Number of subjects	37	72	40
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	63.4	63.3	68.1
standard deviation	± 10.83	± 10.79	± 9.6
Gender categorical			
Units: Subjects			
Female	5	13	4
Male	32	59	36
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	7	1
Native Hawaiian or Other Pacific Islander	0	2	0
Black or African American	2	3	1

White	34	58	35
More than one race	0	0	0
Unknown or Not Reported	0	2	3
Region of Enrollment Units: Subjects			
New Zealand	2	5	4
United States	6	12	4
Italy	12	15	9
Australia	0	3	2
France	12	27	16
Germany	4	7	4
Spain	1	3	1
Alpha-Fetoprotein Units: Subjects			
< 200 nanograms per Liter (µg/L)	9	23	28
200 - 400 (µg/L)	3	5	0
> 400 (µg/L)	23	43	0
Unknown/Not reported	2	1	12

Reporting group values	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib	Part D Cohort 1 - 160 mg LY2157299 + ramucirumab
Number of subjects	3	44	3
Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	70.3	63.7	54.0
standard deviation	± 4.7	± 9.8	± 11.3
Gender categorical Units: Subjects			
Female	0	5	0
Male	3	39	3
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	1	0	0
Asian	0	6	2
Native Hawaiian or Other Pacific Islander	0	7	0
Black or African American	0	2	0
White	2	20	0
More than one race	0	0	0
Unknown or Not Reported	0	9	1
Region of Enrollment Units: Subjects			
New Zealand	0	12	0
United States	1	10	3
Italy	0	4	0
Australia	0	0	0
France	0	14	0
Germany	2	4	0

Spain	0	0	0
Alpha-Fetoprotien			
Units: Subjects			
< 200 nanograms per Liter (µg/L)	2	20	1
200 - 400 (µg/L)	0	4	0
> 400 (µg/L)	1	16	2
Unknown/Not reported	0	4	0

Reporting group values	Part D Cohort 2 - 300 mg LY2157299 + ramucirumab	Total	
Number of subjects	5	204	
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	63.2		
standard deviation	± 11.2	-	
Gender categorical			
Units: Subjects			
Female	0	27	
Male	5	177	
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	1	
Asian	4	21	
Native Hawaiian or Other Pacific Islander	0	9	
Black or African American	1	9	
White	0	149	
More than one race	0	0	
Unknown or Not Reported	0	15	
Region of Enrollment			
Units: Subjects			
New Zealand	0	23	
United States	5	41	
Italy	0	40	
Australia	0	5	
France	0	69	
Germany	0	21	
Spain	0	5	
Alpha-Fetoprotien			
Units: Subjects			
< 200 nanograms per Liter (µg/L)	2	85	
200 - 400 (µg/L)	0	12	
> 400 (µg/L)	2	87	
Unknown/Not reported	1	20	

End points

End points reporting groups

Reporting group title	Part A Cohort 1 - 160 mg LY2157299
Reporting group description: 80 mg LY2157299 given orally given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).	
Reporting group title	Part A Cohort 2 - 300 mg LY2157299
Reporting group description: 150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).	
Reporting group title	Part B - 300 mg LY2157299
Reporting group description: 150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).	
Reporting group title	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Reporting group description: 80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).	
Reporting group title	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib
Reporting group description: 150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).	
Reporting group title	Part D Cohort 1 - 160 mg LY2157299 + ramucirumab
Reporting group description: 80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).	
Reporting group title	Part D Cohort 2 - 300 mg LY2157299 + ramucirumab
Reporting group description: 150 mg LY2157299 given twice orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle).	
Subject analysis set title	Part B LY2157299
Subject analysis set type	Per protocol
Subject analysis set description: 150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).	
Subject analysis set title	Part C LY2157299
Subject analysis set type	Per protocol
Subject analysis set description: 150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).	
Subject analysis set title	Part C Cohort 1 - 160 mg + Sorafenib
Subject analysis set type	Per protocol
Subject analysis set description: 80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib	
Subject analysis set title	LY2157299
Subject analysis set type	Per protocol
Subject analysis set description: LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).	
Subject analysis set title	Part C Cohort 1 - 160mg LY2157299 + Sorafenib
Subject analysis set type	Per protocol
Subject analysis set description: 80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).	

Primary: Change from Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)

End point title	Change from Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS) ^{[1][2]}
-----------------	--

End point description:

Biomarker response was defined as a > 20% decrease in the biomarker AFP from baseline during 8 weeks of treatment. Data presented is median overall survival of those participants who achieved the defined biomarker response. Participants enrolled in Part A had a baseline AFP level of >1.5 upper limit normal (ULN). Participants enrolled in Part B had baseline AFP level <1.5 ULN.

Analysis Population Description (APD): All randomized participants who received at least one dose of study drug, achieved a >20% reduction in biomarker AFP, and had evaluable post-baseline biomarker data. Due to low enrollment into Part C Cohort 1 - 160 mg reporting group, Kaplan Meier analysis for OS was not conducted in this subgroup. Per protocol, Part D collected safety data only.

End point type	Primary
----------------	---------

End point timeframe:

Baseline, discontinuation from any cause (Up to 21 months)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis not available for relationship of AFP to overall survival.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	14	10 ^[3]	27
Units: Months				
median (confidence interval 95%)	19.9 (1.5 to 25.1)	21.5 (2.9 to 34.2)	24.2 (3.0 to 9999)	17.9 (12.6 to 32.8)

Notes:

[3] - Part B 95% CI upper limit was non-estimable.

Statistical analyses

No statistical analyses for this end point

Primary: Change from Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS)

End point title	Change from Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS) ^{[4][5]}
-----------------	--

End point description:

Biomarker response was defined as a > 20% decrease in the biomarker TGF-β from baseline. Data presented is median overall survival of those participants who achieved biomarker response.

APD: All randomized participants who received at least one dose of study drug, achieved a >20% reduction in biomarker TGF-β and had evaluable post-baseline biomarker data. Due to low enrollment in Part C Cohort 1 - 160 mg reporting group, Kaplan Meier analysis for OS was not conducted for this subgroup. Per protocol, Part D collected safety data only.

End point type	Primary
----------------	---------

End point timeframe:

Baseline, discontinuation from any cause (Up to 22 months)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis not available for relationship of TGF- β to overall survival.

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	34	28 ^[6]	31
Units: Months				
median (confidence interval 95%)	11.9 (5.4 to 15.6)	10.1 (4.9 to 15.5)	21.9 (12.4 to 9999)	22.8 (16.2 to 31.8)

Notes:

[6] - Part B 95% CI upper limit was non-estimable.

Statistical analyses

No statistical analyses for this end point

Primary: Time to Progression (TTP)

End point title	Time to Progression (TTP) ^{[7][8]}
-----------------	---

End point description:

TTP is measured from the date of first dose to the first date of progression of disease based on the investigator review of tumor response using Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).

APD: All randomized participants who receive at least one dose of study drug. Per protocol, Part D collected safety data only.

End point type	Primary
----------------	---------

End point timeframe:

Randomization to date of first measured progressive disease (Up to 36 Weeks)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis not available for TTP.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	72	40	3
Units: Weeks				
median (confidence interval 90%)	12.1 (6.3 to 17.6)	7.1 (6.3 to 12.7)	18.0 (10.0 to 24.0)	36.0 (18.0 to 36.0)

End point values	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Weeks				
median (confidence interval 90%)	17.9 (12.1 to 24.0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Population Pharmacokinetics (PK) Mean Population Clearance of Galunisertib

End point title	Population Pharmacokinetics (PK) Mean Population Clearance of Galunisertib
-----------------	--

End point description:

Population mean (between-subject coefficient variance [CV%]) apparent clearance.

APD: All randomized participants who received at least one dose of study drug, regardless of dose, with evaluable PK data. Per protocol, Part D collected safety data only.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1

End point values	LY2157299			
Subject group type	Subject analysis set			
Number of subjects analysed	143			
Units: Liter per hour (L/hr)				
geometric mean (geometric coefficient of variation)	33.6 (± 48)			

Statistical analyses

No statistical analyses for this end point

Secondary: Recommended dose for phase 3 Hepatocellular Carcinoma trials

End point title	Recommended dose for phase 3 Hepatocellular Carcinoma trials
-----------------	--

End point description:

APD: All randomized participants in Part A and Part B at time of decision to focus on 300 mg dose.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to end of study

End point values	LY2157299			
Subject group type	Subject analysis set			
Number of subjects analysed	74			
Units: milligrams (mg)				
number (not applicable)	300			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS) ^[9]
-----------------	--------------------------------------

End point description:

OS duration is measured from the date of first dose to the date of death from any cause.

APD: All randomized participants who received at least one dose of study drug. Per protocol, Part D collected safety data only.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization to date of death from any cause (Up to 104 Weeks)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	72	40	3
Units: Weeks				
median (confidence interval 90%)	39.1 (24.1 to 52.6)	29.6 (19.6 to 38.6)	73.0 (45.4 to 104.7)	30.3 (28.4 to 70.3)

End point values	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Weeks				
median (confidence interval 90%)	89.6 (70.3 to 104.9)			

Statistical analyses

No statistical analyses for this end point

Secondary: Progression free survival (PFS)

End point title	Progression free survival (PFS) ^[10]
-----------------	---

End point description:

PFS duration is measure from the date of first dose to the first date of objective progression of disease or death from any cause.

APD: All randomized participants who received at least one dose of study drug. Per protocol, Part D collected safety data only.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization to measured progressive disease or death from any cause (Up to 45 Weeks)

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	72	40	3
Units: Weeks				
median (confidence interval 90%)	12 (6.3 to 12.6)	6.6 (6.1 to 10.9)	13.4 (7.4 to 23.3)	28.4 (6.0 to 36.0)

End point values	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Weeks				
median (confidence interval 90%)	28.4 (17.4 to 45.3)			

Statistical analyses

Secondary: Percentage of participants achieving an objective response (response rate)

End point title	Percentage of participants achieving an objective response (response rate) ^[11]
-----------------	--

End point description:

The percentage of participants who achieved best overall response of either Complete Response (CR) or Partial Response (PR). The overall response rate for each dose will be estimated by dividing the number of confirmed responders by the number of participants who received at least one dose of study drug.

APD: All randomized participants who received at least one dose of study drug. Per protocol, Part D collected safety data only.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization to measured progressive disease (Up to 36 Weeks)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	46	27	3
Units: percentage of participants				
number (not applicable)				
Complete Response	0	0	0	0
Partial Response	0	0	3.7	0

End point values	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: percentage of participants				
number (not applicable)				
Complete Response	0			
Partial Response	2.3			

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Tumor Response (DoR)

End point title	Duration of Tumor Response (DoR) ^[12]
-----------------	--

End point description:

DoR is measured from the date of the first objective status assessment of a Complete Response (CR) or Partial Response (PR), determined by RECIST v1.1, to the first date of objective progression of disease or death from any cause.

APD: All randomized participants who received at least one dose of study drug. Per protocol, Part D collected safety data only.

End point type	Secondary
----------------	-----------

End point timeframe:

Time of response to measured progressive disease or death from any cause (Up to 84 Weeks)

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[13]	0 ^[14]	37	0 ^[15]
Units: Weeks				
median (confidence interval 90%)	(to)	(to)	37.6 (25.1 to 50.1)	(to)

Notes:

[13] - Only participant who had at least one dose of study drug and assessment of CR or PR were analyzed.

[14] - Only participant who had at least one dose of study drug and assessment of CR or PR were analyzed.

[15] - Only participant who had at least one dose of study drug and assessment of CR or PR were analyzed.

End point values	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Weeks				
median (confidence interval 90%)	40.2 (12.1 to 84.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Treatment Failure (TTF)

End point title	Time to Treatment Failure (TTF) ^[16]
-----------------	---

End point description:

TTF is measured from the date of first dose until the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause.

APD: All randomized participants who received at least one dose of study drug. Per protocol, Part D collected safety data only.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization to the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause (Up to 75 Weeks)

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	72	40	3
Units: Weeks				
median (confidence interval 90%)	13.4 (8.6 to 18.0)	9.9 (8.1 to 12.1)	19.3 (12.1 to 26.3)	26.3 (19.3 to 54.0)

End point values	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Weeks				
median (confidence interval 90%)	49.3 (18.3 to 75.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Functional Assessment of Cancer Therapy, Hepatobiliary (FACT-Hep) sub-scores and total score

End point title	Change from Baseline in Functional Assessment of Cancer Therapy, Hepatobiliary (FACT-Hep) sub-scores and total score ^[17]
-----------------	--

End point description:

FACT-Hep consists of 45 items in five subscales (1) physical well-being (PWB) score range 0 -28; (2) social well-being (SWB) score range 0-28; (3) emotional well-being (EWB) score range 0-24; (4) functional well-being (FWB) score range 0-28; and (5) the hepatobiliary cancer subscale (HCS) Score range 0-72; FACT-Hep score range 1-180, and Trial-Outcome Index (TOI) score range 1-128, to assess health related quality of life in participants with cancer. Higher scores reflect a better health state.

APD: All randomized participants with baseline and one post-baseline FACT-Hep Questionnaire in Cycles 2, 3, or 4. Per protocol, Part D collected safety data only.

End point type	Secondary
End point timeframe:	
Baseline, Day 1 Cycle 4	

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	51	38	3
Units: units on a scale				
arithmetic mean (standard deviation)				
PWB	0.06 (± 3.6)	-0.16 (± 5.0)	0.04 (± 3.4)	-1.67 (± 1.5)
SWB	0.96 (± 2.9)	0.24 (± 3.4)	0.37 (± 4.5)	-1.11 (± 2.8)
EWB	0.55 (± 2.7)	1.17 (± 3.9)	1.13 (± 4.1)	2.87 (± 2.8)
FWB	-0.02 (± 5.3)	0.84 (± 3.6)	1.20 (± 4.7)	-1.00 (± 1.0)
HCS	1.93 (± 7.6)	1.40 (± 7.8)	0.89 (± 6.8)	1.08 (± 6.0)
FACT-Hep	2.04 (± 1.53)	1.50 (± 17.5)	0.58 (± 18.2)	-0.50 (± 6.5)
TOI	1.34 (± 13.3)	1.14 (± 14.6)	1.17 (± 12.2)	-1.92 (± 7.7)

End point values	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib			
Subject group type	Reporting group			
Number of subjects analysed	39			
Units: units on a scale				
arithmetic mean (standard deviation)				
PWB	-1.75 (± 4.4)			
SWB	0.41 (± 3.6)			
EWB	0.85 (± 2.5)			
FWB	-1.19 (± 4.6)			
HCS	-3.79 (± 7.3)			
FACT-Hep	-8.54 (± 17.0)			
TOI	-8.28 (± 13.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Worsening (TTW) of Symptoms (FACT-Hep)

End point title	Time to Worsening (TTW) of Symptoms (FACT-Hep) ^[18]
-----------------	--

End point description:

TTW of symptoms used minimally important differences to evaluate PWB, FWB, Hepatocellular Cancer Symptoms (HCS), NCCN/FACT Hepatocellular Symptoms (FHS), and TOI. PWB TTW was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; FWB TTW was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; HCS TTW was defined as participants who had change in a subscale of ≥ 5 point decrease from baseline; FHS TTW was defined

as participants who had change in a subscale of ≥ 2 point decrease from baseline; TOI TTW was defined as participants who had change in the subscale of ≥ 7 point decrease from baseline

APD: All randomized participants who completed a baseline and one post-baseline FACT-Hep TTW questionnaire. Due to low enrollment in Part C Cohort 1 - 160 mg reporting group, time to event analysis for TTW was not conducted for this subgroup. Per protocol, Part D collected safety data

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to the worsening of symptoms (up to 567 days)

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, Part D collected safety data only.

End point values	Part A Cohort 1 - 160 mg LY2157299	Part A Cohort 2 - 300 mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	61	37	40
Units: Days				
median (confidence interval 95%)				
PWB	114.0 (30.0 to 9999)	113.0 (57.0 to 9999)	113.0 (58.0 to 170.0)	30.0 (29.0 to 57.0)
FWB	57.0 (30.0 to 86.0)	88.0 (57.0 to 371.0)	64.0 (30.0 to 172.0)	30.0 (29.0 to 58.0)
HCS	114.0 (57.0 to 9999)	113.0 (85.0 to 9999)	170.0 (57.0 to 567.0)	31.0 (29.0 to 57.0)
FHS	55.0 (29.0 to 86.0)	57.0 (30.0 to 113.0)	57.0 (30.0 to 113.0)	30.0 (29.0 to 30.0)
TOI	114.0 (57.0 to 9999)	113.0 (58.0 to 371.0)	179.0 (57.0 to 567.0)	30.0 (29.0 to 31.0)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline to end of study (up to 104 Weeks)

Adverse event reporting additional description:

All randomized participants who received at least one dose of study drug. Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

Reporting groups

Reporting group title	Part A Cohort 1 - 160mg LY2157299
-----------------------	-----------------------------------

Reporting group description:

80 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).

Reporting group title	Part B - 300 mg LY2157299
-----------------------	---------------------------

Reporting group description:

150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).

Reporting group title	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
-----------------------	--

Reporting group description:

80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).

Reporting group title	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib
-----------------------	--

Reporting group description:

150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).

Reporting group title	Part A Cohort 2 - 300 mg LY2157299
-----------------------	------------------------------------

Reporting group description:

150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).

Reporting group title	Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab
-----------------------	--

Reporting group description:

150 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).

Reporting group title	Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab
-----------------------	--

Reporting group description:

80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).

Serious adverse events	Part A Cohort 1 - 160mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 1 - 160 mg LY2157299 + Sorafenib
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 37 (40.54%)	16 / 40 (40.00%)	3 / 3 (100.00%)
number of deaths (all causes)	6	1	0
number of deaths resulting from adverse events	2	0	0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
malignant ascites			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
malignant neoplasm progression			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
neoplasm progression			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pancreatic neuroendocrine tumour			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
second primary malignancy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
squamous cell carcinoma			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
squamous cell carcinoma of lung			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
squamous cell carcinoma of skin alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tumour haemorrhage alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tumour pain alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
dry gangrene alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
shock haemorrhagic alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thrombosis alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chest discomfort			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
general physical health deterioration			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyrexia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
dyspnoea			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pleural effusion			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia aspiration			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary embolism			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	2 / 40 (5.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 1	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
pulmonary infarction			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary oedema			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

respiratory failure alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 37 (0.00%) 0 / 0 0 / 0	0 / 40 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
Psychiatric disorders confusional state alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 37 (2.70%) 1 / 2 0 / 0	0 / 40 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
disorientation alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 37 (0.00%) 0 / 0 0 / 0	0 / 40 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
Investigations blood bilirubin increased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 37 (2.70%) 1 / 1 0 / 0	0 / 40 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
liver function test abnormal alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 37 (0.00%) 0 / 0 0 / 0	0 / 40 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
Injury, poisoning and procedural complications cervical vertebral fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all concussion	0 / 37 (0.00%) 0 / 0 0 / 0	0 / 40 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0

alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
exposure during pregnancy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
femur fracture			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pelvic fracture			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post procedural haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
radiation pneumonitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
shunt stenosis			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
toxicity to various agents alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
acute coronary syndrome alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
acute myocardial infarction alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
angina unstable alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atrial fibrillation alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atrial thrombosis alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
left ventricular dysfunction alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
left ventricular failure alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
cerebrovascular accident alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
embolic stroke alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
encephalopathy alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhage intracranial alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic encephalopathy alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
loss of consciousness alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
presyncope alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
transient ischaemic attack alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
anaemia alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	3 / 40 (7.50%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	1 / 2	0 / 5	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
neutropenia alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thrombocytopenia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
abdominal distension			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abdominal pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abdominal pain upper			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ascites			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diarrhoea			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
duodenal ulcer			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastric ulcer			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastric varices haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haematemesis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intestinal obstruction			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

intra-abdominal haemorrhage alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0	
large intestinal haemorrhage alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
lower gastrointestinal haemorrhage alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
melaena alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
nausea alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
oesophageal varices haemorrhage alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
pancreatitis alternative dictionary used: MedDRA 22.0				

subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peritoneal haematoma			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peritoneal haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rectal haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
small intestinal haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
subileus			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
upper gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	2 / 40 (5.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 4	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

varices oesophageal			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	2 / 40 (5.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vomiting			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
acute hepatic failure			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gallbladder rupture			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic failure			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
hepatic haematoma			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic haemorrhage			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatorenal syndrome			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperbilirubinaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
jaundice cholestatic			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
portal vein thrombosis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
drug eruption			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haematuria			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
prerenal failure			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal disorder			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal impairment			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal injury			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary retention			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
back pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chondrocalcinosis pyrophosphate			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
joint effusion			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
musculoskeletal pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myalgia			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteoarthritis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
anal abscess			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthritis bacterial			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cellulitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diverticulitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
endocarditis			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
liver abscess			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lower respiratory tract infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
lung infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteomyelitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
peritonitis bacterial			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

sepsis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
decreased appetite			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dehydration			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fluid retention			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperammonaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperglycaemia			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib	Part A Cohort 2 - 300 mg LY2157299	Part D Cohort 2 -300 mg LY2157299 + Ramucirumab
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 44 (63.64%)	36 / 72 (50.00%)	2 / 5 (40.00%)
number of deaths (all causes)	3	7	1
number of deaths resulting from adverse events	0	1	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
malignant ascites			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
malignant neoplasm progression			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
neoplasm progression			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pancreatic neuroendocrine tumour			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
second primary malignancy			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
squamous cell carcinoma alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
squamous cell carcinoma of lung alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
squamous cell carcinoma of skin alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tumour haemorrhage alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
tumour pain alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders dry gangrene alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
shock haemorrhagic			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
thrombosis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chest discomfort			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
general physical health deterioration			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pain			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyrexia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	2 / 72 (2.78%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
dyspnoea			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 44 (4.55%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pleural effusion			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia aspiration			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary embolism			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary infarction			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary oedema			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory failure			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
confusional state			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
disorientation			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
blood bilirubin increased			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
liver function test abnormal			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
cervical vertebral fracture			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
concussion			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
exposure during pregnancy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
femur fracture			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pelvic fracture			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post procedural haemorrhage alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
radiation pneumonitis alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
shunt stenosis alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
toxicity to various agents alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
acute coronary syndrome alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
acute myocardial infarction alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
angina unstable alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atrial fibrillation alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atrial thrombosis alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
left ventricular dysfunction alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
left ventricular failure alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders cerebrovascular accident alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
embolic stroke			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
encephalopathy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	2 / 72 (2.78%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhage intracranial			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
hepatic encephalopathy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
loss of consciousness			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
presyncope			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

transient ischaemic attack alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 44 (0.00%) 0 / 0 0 / 0	 0 / 72 (0.00%) 0 / 0 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 6 / 44 (13.64%) 8 / 9 0 / 0	 7 / 72 (9.72%) 4 / 16 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
neutropenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 44 (0.00%) 0 / 0 0 / 0	 1 / 72 (1.39%) 1 / 1 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
thrombocytopenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 44 (0.00%) 0 / 0 0 / 0	 0 / 72 (0.00%) 0 / 0 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
Gastrointestinal disorders abdominal distension alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 44 (0.00%) 0 / 0 0 / 0	 1 / 72 (1.39%) 0 / 2 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
abdominal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 44 (2.27%) 1 / 2 0 / 0	 3 / 72 (4.17%) 0 / 3 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
abdominal pain upper alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ascites			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 44 (4.55%)	4 / 72 (5.56%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diarrhoea			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
duodenal ulcer			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastric ulcer			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastric varices haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

haematemesis				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
intestinal obstruction				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
intra-abdominal haemorrhage				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
large intestinal haemorrhage				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
lower gastrointestinal haemorrhage				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
melaena				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
nausea				
alternative dictionary used: MedDRA 22.0				

subjects affected / exposed	1 / 44 (2.27%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
oesophageal varices haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pancreatitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peritoneal haematoma			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peritoneal haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rectal haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
small intestinal haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

subileus alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
upper gastrointestinal haemorrhage alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
varices oesophageal alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vomiting alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
acute hepatic failure alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
gallbladder rupture alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic failure alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 44 (2.27%)	2 / 72 (2.78%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
hepatic haematoma			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic haemorrhage			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	2 / 72 (2.78%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	2 / 72 (2.78%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatorenal syndrome			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
hyperbilirubinaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
jaundice cholestatic			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

portal vein thrombosis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 44 (0.00%) 0 / 0 0 / 0	 1 / 72 (1.39%) 0 / 1 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
Skin and subcutaneous tissue disorders drug eruption alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 44 (0.00%) 0 / 0 0 / 0	 0 / 72 (0.00%) 0 / 0 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
Renal and urinary disorders acute kidney injury alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 44 (2.27%) 0 / 1 0 / 0	 2 / 72 (2.78%) 0 / 2 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
haematuria alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 1 / 44 (2.27%) 0 / 2 0 / 0	 0 / 72 (0.00%) 0 / 0 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
prerenal failure alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 44 (0.00%) 0 / 0 0 / 0	 0 / 72 (0.00%) 0 / 0 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
renal disorder alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 44 (0.00%) 0 / 0 0 / 0	 1 / 72 (1.39%) 0 / 1 0 / 0	 0 / 5 (0.00%) 0 / 0 0 / 0
renal impairment alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal injury			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary retention			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
back pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	2 / 72 (2.78%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chondrocalcinosis pyrophosphate			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
joint effusion			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
musculoskeletal pain			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myalgia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteoarthritis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
anal abscess			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthritis bacterial			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cellulitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diverticulitis			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
endocarditis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
liver abscess			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 44 (4.55%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lower respiratory tract infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lung infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteomyelitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peritonitis bacterial			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

pneumonia alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	4 / 72 (5.56%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 2	0 / 0
sepsis alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract infection alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
decreased appetite alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dehydration alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fluid retention alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperammonaemia alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperglycaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
malignant ascites			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
malignant neoplasm progression			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
neoplasm progression			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pancreatic neuroendocrine tumour			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
second primary malignancy alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
squamous cell carcinoma alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
squamous cell carcinoma of lung alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
squamous cell carcinoma of skin alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
tumour haemorrhage alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
tumour pain alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Vascular disorders			
dry gangrene			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
shock haemorrhagic			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
thrombosis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
chest discomfort			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
general physical health deterioration			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pain			

alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pyrexia				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
dyspnoea				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pleural effusion				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonia aspiration				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonitis				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pulmonary embolism				
alternative dictionary used: MedDRA 22.0				

subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pulmonary infarction			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pulmonary oedema			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
respiratory failure			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
confusional state			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
disorientation			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
blood bilirubin increased			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
liver function test abnormal			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
cervical vertebral fracture			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
concussion			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
exposure during pregnancy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
femur fracture			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pelvic fracture			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
post procedural haemorrhage alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
radiation pneumonitis alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
shunt stenosis alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
toxicity to various agents alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
acute coronary syndrome alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
acute myocardial infarction alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
angina unstable			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
atrial fibrillation			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
atrial thrombosis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
left ventricular dysfunction			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
left ventricular failure			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
cerebrovascular accident			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
embolic stroke				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	1 / 3 (33.33%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
encephalopathy				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
haemorrhage intracranial				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hepatic encephalopathy				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
loss of consciousness				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
presyncope				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

transient ischaemic attack alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
neutropenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
thrombocytopenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
Gastrointestinal disorders abdominal distension alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
abdominal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
abdominal pain upper alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ascites				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
diarrhoea				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
duodenal ulcer				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastric ulcer				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastric varices haemorrhage				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastrointestinal haemorrhage				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

haematemesis				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
intestinal obstruction				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
intra-abdominal haemorrhage				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
large intestinal haemorrhage				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lower gastrointestinal haemorrhage				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
melaena				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
nausea				
alternative dictionary used: MedDRA 22.0				

subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
oesophageal varices haemorrhage alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pancreatitis alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
peritoneal haematoma alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
peritoneal haemorrhage alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
rectal haemorrhage alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
small intestinal haemorrhage alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

subileus alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
upper gastrointestinal haemorrhage alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
varices oesophageal alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
vomiting alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
Hepatobiliary disorders acute hepatic failure alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
gallbladder rupture alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
hepatic failure alternative dictionary used: MedDRA 22.0				

subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hepatic haematoma				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hepatic haemorrhage				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hepatic pain				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hepatorenal syndrome				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hyperbilirubinaemia				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
jaundice cholestatic				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

portal vein thrombosis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
Skin and subcutaneous tissue disorders drug eruption alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
Renal and urinary disorders acute kidney injury alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
haematuria alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
prerenal failure alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
renal disorder alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0		
renal impairment alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
renal injury				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
urinary retention				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal and connective tissue disorders				
back pain				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
chondrocalcinosis pyrophosphate				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
joint effusion				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
musculoskeletal pain				
alternative dictionary used: MedDRA 22.0				

subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
myalgia				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
osteoarthritis				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
anal abscess				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
arthritis bacterial				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cellulitis				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
diverticulitis				
alternative dictionary used: MedDRA 22.0				

subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
endocarditis				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
liver abscess				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lower respiratory tract infection				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lung infection				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
osteomyelitis				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
peritonitis bacterial				
alternative dictionary used: MedDRA 22.0				
subjects affected / exposed	0 / 3 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

pneumonia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
sepsis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
urinary tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
Metabolism and nutrition disorders decreased appetite alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
dehydration alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
fluid retention alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0			
hyperammonaemia alternative dictionary used: MedDRA 22.0				

subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
hyperglycaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Part A Cohort 1 - 160mg LY2157299	Part B - 300 mg LY2157299	Part C Cohort 1 - 160 mg LY2157299 +Sorafenib
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 37 (86.49%)	38 / 40 (95.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
basal cell carcinoma			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
malignant ascites			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
tumour pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	4 / 37 (10.81%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	4	1	0
Vascular disorders			
flushing			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
haematoma			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
hypertension			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	2 / 40 (5.00%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	5 / 37 (13.51%)	4 / 40 (10.00%)	0 / 3 (0.00%)
occurrences (all)	6	8	0
chills			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 37 (8.11%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
fatigue			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	9 / 37 (24.32%)	14 / 40 (35.00%)	2 / 3 (66.67%)
occurrences (all)	10	15	2
influenza like illness			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	4 / 40 (10.00%)	0 / 3 (0.00%)
occurrences (all)	1	4	0
localised oedema			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
non-cardiac chest pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
oedema peripheral			
alternative dictionary used: MedDRA 22.0			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pyrexia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 37 (13.51%)</p> <p>6</p> <p>0 / 37 (0.00%)</p> <p>0</p> <p>2 / 37 (5.41%)</p> <p>4</p>	<p>12 / 40 (30.00%)</p> <p>17</p> <p>0 / 40 (0.00%)</p> <p>0</p> <p>2 / 40 (5.00%)</p> <p>2</p>	<p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p> <p>1 / 3 (33.33%)</p> <p>1</p>
<p>Reproductive system and breast disorders</p> <p>erectile dysfunction</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed^[1]</p> <p>occurrences (all)</p>	<p>1 / 32 (3.13%)</p> <p>1</p>	<p>0 / 36 (0.00%)</p> <p>0</p>	<p>0 / 3 (0.00%)</p> <p>0</p>
<p>Respiratory, thoracic and mediastinal disorders</p> <p>cough</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dyspnoea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>epistaxis</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 37 (8.11%)</p> <p>3</p> <p>3 / 37 (8.11%)</p> <p>3</p> <p>1 / 37 (2.70%)</p> <p>3</p> <p>1 / 37 (2.70%)</p> <p>1</p>	<p>3 / 40 (7.50%)</p> <p>4</p> <p>6 / 40 (15.00%)</p> <p>7</p> <p>3 / 40 (7.50%)</p> <p>3</p> <p>1 / 40 (2.50%)</p> <p>1</p>	<p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p>
Psychiatric disorders			

anxiety alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	1 / 37 (2.70%) 1	0 / 40 (0.00%) 0	0 / 3 (0.00%) 0
confusional state alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 37 (5.41%) 2	0 / 40 (0.00%) 0	0 / 3 (0.00%) 0
insomnia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 37 (5.41%) 2	4 / 40 (10.00%) 4	0 / 3 (0.00%) 0
Investigations aspartate aminotransferase increased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	2 / 37 (5.41%) 3	2 / 40 (5.00%) 2	1 / 3 (33.33%) 1
blood alkaline phosphatase increased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	1 / 40 (2.50%) 1	1 / 3 (33.33%) 1
blood bilirubin increased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	1 / 37 (2.70%) 1	2 / 40 (5.00%) 2	0 / 3 (0.00%) 0
haemoglobin decreased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	0 / 40 (0.00%) 0	1 / 3 (33.33%) 1
weight decreased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	4 / 37 (10.81%) 5	10 / 40 (25.00%) 17	3 / 3 (100.00%) 7
weight increased alternative dictionary used:			

MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Injury, poisoning and procedural complications			
fall			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Nervous system disorders			
embolic stroke			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
headache			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	5 / 40 (12.50%)	0 / 3 (0.00%)
occurrences (all)	1	5	0
hepatic encephalopathy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
peripheral sensory neuropathy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 37 (8.11%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
somnolence			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
taste disorder			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			

<p>anaemia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>9 / 37 (24.32%)</p> <p>22</p>	<p>10 / 40 (25.00%)</p> <p>20</p>	<p>1 / 3 (33.33%)</p> <p>4</p>
<p>neutropenia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 37 (8.11%)</p> <p>9</p>	<p>1 / 40 (2.50%)</p> <p>1</p>	<p>0 / 3 (0.00%)</p> <p>0</p>
<p>thrombocytopenia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 37 (5.41%)</p> <p>2</p>	<p>3 / 40 (7.50%)</p> <p>9</p>	<p>0 / 3 (0.00%)</p> <p>0</p>
<p>Ear and labyrinth disorders</p> <p>tinnitus</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 37 (0.00%)</p> <p>0</p>	<p>3 / 40 (7.50%)</p> <p>3</p>	<p>0 / 3 (0.00%)</p> <p>0</p>
<p>vertigo</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 37 (0.00%)</p> <p>0</p>	<p>1 / 40 (2.50%)</p> <p>1</p>	<p>1 / 3 (33.33%)</p> <p>1</p>
<p>Gastrointestinal disorders</p> <p>abdominal distension</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 37 (5.41%)</p> <p>3</p>	<p>5 / 40 (12.50%)</p> <p>5</p>	<p>0 / 3 (0.00%)</p> <p>0</p>
<p>abdominal pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>7 / 37 (18.92%)</p> <p>7</p>	<p>8 / 40 (20.00%)</p> <p>10</p>	<p>1 / 3 (33.33%)</p> <p>1</p>
<p>abdominal pain upper</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 37 (2.70%)</p> <p>1</p>	<p>4 / 40 (10.00%)</p> <p>4</p>	<p>0 / 3 (0.00%)</p> <p>0</p>
ascites			

alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	5 / 37 (13.51%)	2 / 40 (5.00%)	0 / 3 (0.00%)
occurrences (all)	7	3	0
barrett's oesophagus			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
constipation			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	5 / 37 (13.51%)	7 / 40 (17.50%)	0 / 3 (0.00%)
occurrences (all)	6	7	0
diarrhoea			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	5 / 37 (13.51%)	11 / 40 (27.50%)	1 / 3 (33.33%)
occurrences (all)	8	15	2
dry mouth			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	2 / 40 (5.00%)	1 / 3 (33.33%)
occurrences (all)	1	2	1
flatulence			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	1 / 40 (2.50%)	2 / 3 (66.67%)
occurrences (all)	3	1	2
gingival bleeding			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
nausea			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	6 / 37 (16.22%)	9 / 40 (22.50%)	1 / 3 (33.33%)
occurrences (all)	11	9	2
portal hypertensive gastropathy			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
stomatitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
varices oesophageal			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
vomiting			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	6 / 37 (16.22%)	6 / 40 (15.00%)	1 / 3 (33.33%)
occurrences (all)	6	11	1
Hepatobiliary disorders			
hyperbilirubinaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 37 (8.11%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	5	1	0
portal vein thrombosis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
alopecia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
dry skin			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
erythema multiforme			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
night sweats			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences (all)	2	0	1
palmar-plantar erythrodysaesthesia syndrome			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	1 / 3 (33.33%)
occurrences (all)	0	1	3
pruritus			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	7 / 37 (18.92%)	8 / 40 (20.00%)	1 / 3 (33.33%)
occurrences (all)	9	10	1
rash			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	3
rash maculo-papular			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 37 (8.11%)	2 / 40 (5.00%)	1 / 3 (33.33%)
occurrences (all)	3	2	1
skin exfoliation			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
skin lesion			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
haematuria			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 37 (2.70%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
nocturia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 37 (8.11%)	5 / 40 (12.50%)	0 / 3 (0.00%)
occurrences (all)	5	5	0
back pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	3	2	0
muscle spasms			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 37 (5.41%)	5 / 40 (12.50%)	0 / 3 (0.00%)
occurrences (all)	2	7	0
muscular weakness			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
musculoskeletal chest pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
myalgia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
pain in extremity			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	1	2	0
Infections and infestations			
bronchitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	4 / 40 (10.00%)	0 / 3 (0.00%)
occurrences (all)	0	4	0
furuncle			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
lung infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
post abortion infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed ^[2]	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 37 (2.70%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
urinary tract infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	1 / 3 (33.33%)
occurrences (all)	0	2	1
vaginal infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed ^[3]	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
viral infection			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 37 (0.00%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
vulvovaginal candidiasis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed ^[4]	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
decreased appetite			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	6 / 37 (16.22%)	7 / 40 (17.50%)	2 / 3 (66.67%)
occurrences (all)	7	7	2
hypercalcaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 37 (8.11%)	0 / 40 (0.00%)	0 / 3 (0.00%)
occurrences (all)	4	0	0
hypoalbuminaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	2 / 40 (5.00%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
hypokalaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 37 (0.00%)	1 / 40 (2.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	Part C Cohort 2 - 300 mg LY2157299 + Sorafenib	Part A Cohort 2 - 300 mg LY2157299	Part D Cohort 2 -300 mg LY2157299 + Ramucirumab
Total subjects affected by non-serious adverse events			
subjects affected / exposed	44 / 44 (100.00%)	64 / 72 (88.89%)	5 / 5 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
basal cell carcinoma			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
malignant ascites			
alternative dictionary used: MedDRA 22.0			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>tumour pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 44 (0.00%)</p> <p>0</p> <p>0 / 44 (0.00%)</p> <p>0</p>	<p>5 / 72 (6.94%)</p> <p>5</p> <p>1 / 72 (1.39%)</p> <p>1</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>
<p>Vascular disorders</p> <p>flushing</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>haematoma</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>hypertension</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 44 (6.82%)</p> <p>3</p> <p>4 / 44 (9.09%)</p> <p>4</p> <p>8 / 44 (18.18%)</p> <p>10</p>	<p>2 / 72 (2.78%)</p> <p>3</p> <p>1 / 72 (1.39%)</p> <p>1</p> <p>1 / 72 (1.39%)</p> <p>1</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>
<p>General disorders and administration site conditions</p> <p>asthenia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>chills</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>fatigue</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>influenza like illness</p> <p>alternative dictionary used: MedDRA 22.0</p>	<p>6 / 44 (13.64%)</p> <p>14</p> <p>1 / 44 (2.27%)</p> <p>1</p> <p>11 / 44 (25.00%)</p> <p>16</p>	<p>6 / 72 (8.33%)</p> <p>6</p> <p>2 / 72 (2.78%)</p> <p>3</p> <p>14 / 72 (19.44%)</p> <p>17</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>1 / 5 (20.00%)</p> <p>1</p> <p>2 / 5 (40.00%)</p> <p>4</p>

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 44 (6.82%)</p> <p>3</p>	<p>1 / 72 (1.39%)</p> <p>1</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>localised oedema</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 44 (0.00%)</p> <p>0</p>	<p>1 / 72 (1.39%)</p> <p>1</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>non-cardiac chest pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 44 (0.00%)</p> <p>0</p>	<p>2 / 72 (2.78%)</p> <p>2</p>	<p>1 / 5 (20.00%)</p> <p>1</p>
<p>oedema peripheral</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>10 / 44 (22.73%)</p> <p>12</p>	<p>14 / 72 (19.44%)</p> <p>16</p>	<p>1 / 5 (20.00%)</p> <p>1</p>
<p>pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 44 (0.00%)</p> <p>0</p>	<p>1 / 72 (1.39%)</p> <p>1</p>	<p>1 / 5 (20.00%)</p> <p>1</p>
<p>pyrexia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 44 (11.36%)</p> <p>13</p>	<p>6 / 72 (8.33%)</p> <p>8</p>	<p>1 / 5 (20.00%)</p> <p>1</p>
<p>Reproductive system and breast disorders</p> <p>erectile dysfunction</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed^[1]</p> <p>occurrences (all)</p>	<p>2 / 39 (5.13%)</p> <p>2</p>	<p>0 / 59 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>Respiratory, thoracic and mediastinal disorders</p> <p>cough</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dyspnoea</p> <p>alternative dictionary used: MedDRA 22.0</p>	<p>3 / 44 (6.82%)</p> <p>4</p>	<p>5 / 72 (6.94%)</p> <p>5</p>	<p>1 / 5 (20.00%)</p> <p>1</p>

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>epistaxis</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 44 (11.36%)</p> <p>5</p> <p>4 / 44 (9.09%)</p> <p>5</p> <p>1 / 44 (2.27%)</p> <p>1</p>	<p>9 / 72 (12.50%)</p> <p>10</p> <p>2 / 72 (2.78%)</p> <p>2</p> <p>1 / 72 (1.39%)</p> <p>1</p>	<p>1 / 5 (20.00%)</p> <p>2</p> <p>1 / 5 (20.00%)</p> <p>1</p> <p>1 / 5 (20.00%)</p> <p>1</p>
<p>Psychiatric disorders</p> <p>anxiety</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>confusional state</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>insomnia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 44 (0.00%)</p> <p>0</p> <p>0 / 44 (0.00%)</p> <p>0</p> <p>5 / 44 (11.36%)</p> <p>5</p>	<p>4 / 72 (5.56%)</p> <p>4</p> <p>1 / 72 (1.39%)</p> <p>1</p> <p>5 / 72 (6.94%)</p> <p>6</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>1 / 5 (20.00%)</p> <p>1</p> <p>0 / 5 (0.00%)</p> <p>0</p>
<p>Investigations</p> <p>aspartate aminotransferase increased</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>blood alkaline phosphatase increased</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>blood bilirubin increased</p> <p>alternative dictionary used: MedDRA 22.0</p>	<p>3 / 44 (6.82%)</p> <p>3</p> <p>2 / 44 (4.55%)</p> <p>2</p>	<p>3 / 72 (4.17%)</p> <p>3</p> <p>1 / 72 (1.39%)</p> <p>1</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>

subjects affected / exposed	1 / 44 (2.27%)	3 / 72 (4.17%)	1 / 5 (20.00%)
occurrences (all)	1	3	1
haemoglobin decreased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
weight decreased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	24 / 44 (54.55%)	8 / 72 (11.11%)	0 / 5 (0.00%)
occurrences (all)	58	8	0
weight increased			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	7 / 72 (9.72%)	0 / 5 (0.00%)
occurrences (all)	0	8	0
Injury, poisoning and procedural complications			
fall			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
embolic stroke			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
headache			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 44 (6.82%)	4 / 72 (5.56%)	1 / 5 (20.00%)
occurrences (all)	3	4	1
hepatic encephalopathy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
peripheral sensory neuropathy			
alternative dictionary used: MedDRA 22.0			

<p>subjects affected / exposed</p> <p>0 / 44 (0.00%)</p> <p>0 / 72 (0.00%)</p> <p>0 / 5 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>0</p> <p>0</p>			
<p>somnolence</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>0 / 44 (0.00%)</p> <p>1 / 72 (1.39%)</p> <p>0 / 5 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>1</p> <p>0</p>			
<p>taste disorder</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>1 / 44 (2.27%)</p> <p>0 / 72 (0.00%)</p> <p>1 / 5 (20.00%)</p> <p>occurrences (all)</p> <p>1</p> <p>0</p> <p>1</p>			
<p>Blood and lymphatic system disorders</p> <p>anaemia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>12 / 44 (27.27%)</p> <p>13 / 72 (18.06%)</p> <p>0 / 5 (0.00%)</p> <p>occurrences (all)</p> <p>17</p> <p>23</p> <p>0</p>			
<p>neutropenia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>1 / 44 (2.27%)</p> <p>3 / 72 (4.17%)</p> <p>0 / 5 (0.00%)</p> <p>occurrences (all)</p> <p>1</p> <p>4</p> <p>0</p>			
<p>thrombocytopenia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>7 / 44 (15.91%)</p> <p>2 / 72 (2.78%)</p> <p>0 / 5 (0.00%)</p> <p>occurrences (all)</p> <p>22</p> <p>2</p> <p>0</p>			
<p>Ear and labyrinth disorders</p> <p>tinnitus</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>2 / 44 (4.55%)</p> <p>0 / 72 (0.00%)</p> <p>0 / 5 (0.00%)</p> <p>occurrences (all)</p> <p>2</p> <p>0</p> <p>0</p>			
<p>vertigo</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>0 / 44 (0.00%)</p> <p>1 / 72 (1.39%)</p> <p>0 / 5 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>1</p> <p>0</p>			
<p>Gastrointestinal disorders</p> <p>abdominal distension</p> <p>alternative dictionary used: MedDRA 22.0</p>			

subjects affected / exposed	4 / 44 (9.09%)	2 / 72 (2.78%)	2 / 5 (40.00%)
occurrences (all)	4	2	2
abdominal pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	7 / 44 (15.91%)	11 / 72 (15.28%)	2 / 5 (40.00%)
occurrences (all)	8	12	2
abdominal pain upper			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	4 / 44 (9.09%)	7 / 72 (9.72%)	1 / 5 (20.00%)
occurrences (all)	5	10	1
ascites			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	6 / 44 (13.64%)	8 / 72 (11.11%)	0 / 5 (0.00%)
occurrences (all)	8	8	0
barrett's oesophagus			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
constipation			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	6 / 44 (13.64%)	11 / 72 (15.28%)	1 / 5 (20.00%)
occurrences (all)	8	14	1
diarrhoea			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	21 / 44 (47.73%)	10 / 72 (13.89%)	1 / 5 (20.00%)
occurrences (all)	43	13	1
dry mouth			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 44 (4.55%)	4 / 72 (5.56%)	0 / 5 (0.00%)
occurrences (all)	2	4	0
flatulence			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 44 (6.82%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	3	0	0

gingival bleeding alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 72 (0.00%) 0	0 / 5 (0.00%) 0
nausea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	12 / 44 (27.27%) 17	15 / 72 (20.83%) 21	1 / 5 (20.00%) 1
portal hypertensive gastropathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 72 (0.00%) 0	0 / 5 (0.00%) 0
stomatitis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	5 / 44 (11.36%) 8	3 / 72 (4.17%) 3	0 / 5 (0.00%) 0
varices oesophageal alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	2 / 72 (2.78%) 2	0 / 5 (0.00%) 0
vomiting alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	5 / 44 (11.36%) 11	12 / 72 (16.67%) 17	0 / 5 (0.00%) 0
Hepatobiliary disorders hyperbilirubinaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	4 / 44 (9.09%) 5	3 / 72 (4.17%) 3	0 / 5 (0.00%) 0
portal vein thrombosis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	1 / 72 (1.39%) 1	1 / 5 (20.00%) 1
Skin and subcutaneous tissue disorders			

alopecia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	9 / 44 (20.45%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences (all)	9	1	0
dry skin			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	7 / 44 (15.91%)	3 / 72 (4.17%)	0 / 5 (0.00%)
occurrences (all)	7	3	0
erythema multiforme			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
night sweats			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
palmar-plantar erythrodysaesthesia syndrome			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	28 / 44 (63.64%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences (all)	61	1	0
pruritus			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	12 / 44 (27.27%)	9 / 72 (12.50%)	0 / 5 (0.00%)
occurrences (all)	16	10	0
rash			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	10 / 44 (22.73%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences (all)	11	1	0
rash maculo-papular			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 44 (2.27%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences (all)	2	1	0
skin exfoliation			
alternative dictionary used: MedDRA 22.0			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>skin lesion</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 44 (6.82%)</p> <p>3</p> <p>3 / 44 (6.82%)</p> <p>3</p>	<p>0 / 72 (0.00%)</p> <p>0</p> <p>0 / 72 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>
<p>Renal and urinary disorders</p> <p>haematuria</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nocturia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 44 (6.82%)</p> <p>3</p> <p>0 / 44 (0.00%)</p> <p>0</p>	<p>0 / 72 (0.00%)</p> <p>0</p> <p>2 / 72 (2.78%)</p> <p>2</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>1 / 5 (20.00%)</p> <p>1</p>
<p>Musculoskeletal and connective tissue disorders</p> <p>arthralgia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>back pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>muscle spasms</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>muscular weakness</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>musculoskeletal chest pain</p> <p>alternative dictionary used: MedDRA 22.0</p>	<p>6 / 44 (13.64%)</p> <p>6</p> <p>3 / 44 (6.82%)</p> <p>3</p> <p>6 / 44 (13.64%)</p> <p>7</p> <p>1 / 44 (2.27%)</p> <p>1</p>	<p>3 / 72 (4.17%)</p> <p>3</p> <p>5 / 72 (6.94%)</p> <p>9</p> <p>2 / 72 (2.78%)</p> <p>3</p> <p>0 / 72 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>

subjects affected / exposed	1 / 44 (2.27%)	2 / 72 (2.78%)	0 / 5 (0.00%)
occurrences (all)	1	3	0
myalgia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	10 / 44 (22.73%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences (all)	11	1	0
pain in extremity			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 44 (6.82%)	3 / 72 (4.17%)	0 / 5 (0.00%)
occurrences (all)	6	3	0
Infections and infestations			
bronchitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 44 (4.55%)	3 / 72 (4.17%)	0 / 5 (0.00%)
occurrences (all)	2	3	0
furuncle			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 44 (6.82%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	3	0	0
lung infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 44 (6.82%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	7	0	0
post abortion infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed ^[2]	1 / 5 (20.00%)	0 / 13 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 44 (4.55%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences (all)	3	1	0
urinary tract infection			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	5 / 44 (11.36%)	2 / 72 (2.78%)	0 / 5 (0.00%)
occurrences (all)	5	2	0
vaginal infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed ^[3]	1 / 5 (20.00%)	0 / 13 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
viral infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	0 / 72 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
vulvovaginal candidiasis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed ^[4]	1 / 5 (20.00%)	0 / 13 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
decreased appetite			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	10 / 44 (22.73%)	7 / 72 (9.72%)	0 / 5 (0.00%)
occurrences (all)	15	8	0
hypercalcaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 44 (0.00%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences (all)	0	2	0
hypoalbuminaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	3 / 44 (6.82%)	3 / 72 (4.17%)	0 / 5 (0.00%)
occurrences (all)	3	4	0
hypokalaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	4 / 44 (9.09%)	1 / 72 (1.39%)	0 / 5 (0.00%)
occurrences (all)	6	1	0
Non-serious adverse events	Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab		
Total subjects affected by non-serious adverse events			

subjects affected / exposed	3 / 3 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
basal cell carcinoma			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
malignant ascites			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
tumour pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
Vascular disorders			
flushing			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
haematoma			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
hypertension			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
chills			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
fatigue			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
influenza like illness			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
localised oedema			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
non-cardiac chest pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
oedema peripheral			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
pyrexia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
erectile dysfunction			
alternative dictionary used: MedDRA 22.0			

subjects affected / exposed ^[1] occurrences (all)	0 / 3 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders cough alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) dyspnoea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) epistaxis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) oropharyngeal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0 1 / 3 (33.33%) 1 3 / 3 (100.00%) 3 0 / 3 (0.00%) 0		
Psychiatric disorders anxiety alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) confusional state alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) insomnia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0		
Investigations			

aspartate aminotransferase increased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
blood alkaline phosphatase increased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
blood bilirubin increased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
haemoglobin decreased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
weight decreased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
weight increased alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
Injury, poisoning and procedural complications fall alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
Nervous system disorders embolic stroke alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1		

headache alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
hepatic encephalopathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
peripheral sensory neuropathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
somnolence alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
taste disorder alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
neutropenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
thrombocytopenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
Ear and labyrinth disorders			

tinnitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
vertigo alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
Gastrointestinal disorders abdominal distension alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1		
abdominal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
abdominal pain upper alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
ascites alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
barrett's oesophagus alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
constipation alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0		
diarrhoea alternative dictionary used: MedDRA 22.0			

subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
dry mouth			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
flatulence			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
gingival bleeding			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
nausea			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
portal hypertensive gastropathy			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
stomatitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
varices oesophageal			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
vomiting			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		

Hepatobiliary disorders hyperbilirubinaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) portal vein thrombosis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0		
Skin and subcutaneous tissue disorders alopecia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) dry skin alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) erythema multiforme alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) night sweats alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) palmar-plantar erythrodysaesthesia syndrome alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) pruritus alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) rash	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0		

<p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>rash maculo-papular</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>skin exfoliation</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>skin lesion</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>Renal and urinary disorders</p> <p>haematuria</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nocturia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>arthralgia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>back pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>muscle spasms</p> <p>alternative dictionary used:</p>	<p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p>		

MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
muscular weakness			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
musculoskeletal chest pain			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	2 / 3 (66.67%)		
occurrences (all)	2		
myalgia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
pain in extremity			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
Infections and infestations			
bronchitis			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
furuncle			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
lung infection			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
post abortion infection			
alternative dictionary used: MedDRA 22.0			

<p>subjects affected / exposed^[2]</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>upper respiratory tract infection</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 3 (33.33%)</p> <p>1</p>		
<p>urinary tract infection</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>vaginal infection</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed^[3]</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>viral infection</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 3 (33.33%)</p> <p>1</p>		
<p>vulvovaginal candidiasis</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed^[4]</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>Metabolism and nutrition disorders</p> <p>decreased appetite</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>hypercalcaemia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 3 (0.00%)</p> <p>0</p>		
<p>hypoalbuminaemia</p> <p>alternative dictionary used: MedDRA 22.0</p>			

subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		
hypokalaemia			
alternative dictionary used: MedDRA 22.0			
subjects affected / exposed	0 / 3 (0.00%)		
occurrences (all)	0		

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 July 2013	Amendment (c): Part C of the study was modified to evaluate the safety of sorafenib when combined with LY2157299 in patients with first-line HCC and Child-Pugh A status. Added a treatment extension to allow participants benefitting from study treatment to continue same study treatment once study endpoint was met.
18 August 2018	Amendment (e): Added treatment arm (Part E) to explore LY2157299 given at 150 mg twice daily for 21 days, followed by 7 days off drug, however Part E was never implemented.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
01 October 2016	Enrollment into Part D was stopped due to challenges of enrollment and lack of efficacy. Part D was only conducted at USA sites, and only safety data was collected.	-

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Per protocol, Part D collected safety data only.

Notes: